-       Report 
- June 2025
-  233 Pages 
- Global 
   From       €2226EUR$2,500USD£1,943GBP 
          -       Report 
- October 2025
-  386 Pages 
- Global 
   From       €5210EUR$5,850USD£4,547GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €3998EUR$4,490USD£3,490GBP 
          -       Report 
- July 2025
-  175 Pages 
- Global 
   From       €3998EUR$4,490USD£3,490GBP 
          -       Report 
- March 2025
-  290 Pages 
- Global 
   From       €3998EUR$4,490USD£3,490GBP 
           -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €3998EUR$4,490USD£3,490GBP 
          -       Report 
- February 2025
-  181 Pages 
- Global 
   From       €4007EUR$4,500USD£3,497GBP 
          -       Report 
- January 2025
-  144 Pages 
- Global 
   From       €3518EUR$3,950USD£3,070GBP 
          -       Report 
- September 2025
-  70 Pages 
- Global 
   From       €3500EUR$4,210USD£3,162GBP 
          -       Report 
- May 2021
-  177 Pages 
- United States 
        €1331EUR$1,495USD£1,162GBP 
          -       Report 
- February 2023
-  152 Pages 
- Global 
   From       €2226EUR$2,500USD£1,943GBP 
          -       Report 
- October 2022
-  119 Pages 
- Global 
   From       €4007EUR$4,500USD£3,497GBP 
          -       Report 
- January 2024
-  200 Pages 
- Global 
   From       €3696EUR$4,150USD£3,225GBP 
          -       Report 
- October 2023
-  145 Pages 
- Global 
   From       €2805EUR$3,150USD£2,448GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5664EUR$6,360USD£4,943GBP 
      €7080EUR$7,950USD£6,179GBP 
            -       Report 
- February 2024
-  120 Pages 
- Asia Pacific 
   From       €3526EUR$3,960USD£3,078GBP 
      €4408EUR$4,950USD£3,847GBP 
            -       Report 
- February 2023
-  198 Pages 
- Global 
   From       €5343EUR$6,000USD£4,663GBP 
      €6679EUR$7,500USD£5,829GBP 
            -       Report 
- February 2023
-  99 Pages 
- Global 
   From       €2814EUR$3,160USD£2,456GBP 
      €3518EUR$3,950USD£3,070GBP 
          -       Report 
- February 2024
-  120 Pages 
- Global 
   From       €4230EUR$4,750USD£3,692GBP 
          -       Report 
- September 2022
-  149 Pages 
- Global 
   From       €3206EUR$3,600USD£2,798GBP 
       
      The Insomnia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Insomnia drugs are used to treat difficulty sleeping, and can be divided into two categories: sedative-hypnotics and non-sedative hypnotics. Sedative-hypnotics are drugs that act on the central nervous system to induce sleep, while non-sedative hypnotics are drugs that act on the brain to improve sleep quality without causing sedation. Commonly prescribed    insomnia drugs include benzodiazepines, non-benzodiazepines, and melatonin receptor agonists.
Some companies in the Insomnia Drug market include Sanofi, Pfizer, Merck, GlaxoSmithKline, and Takeda. Show Less   Read more